Citigroup INC

Citigroup Inc. announced robust second quarter 2026 financial results, with net income soaring 45% year-over-year to $5.8 billion on revenues of $24.8 billion.

Citigroup Inc. held its 2026 Annual Meeting of Stockholders, where key proposals including an amendment to the 2019 Stock Incentive Plan and the election of directors were approved.

Citigroup Inc. announced a robust first quarter 2026 with revenues up 14% and net income soaring 42%, driven by broad-based growth across its five interconnected businesses.

Citigroup Inc. filed a Form 8-K to disclose changes in its reporting structure for the first quarter of 2026, including business segment reclassifications and updated tangible common equity allocation methodologies.

Citigroup's Compensation Committee approved a $42 million incentive compensation package for CEO Jane Fraser for her 2025 performance, citing significant improvements across key business areas and strong stock performance.

Citigroup Inc. has established and issued a new series of 6.500% Fixed Rate Reset Noncumulative Preferred Stock, Series JJ, totaling $1 billion in liquidation preference.

Citigroup Inc. announced a significant increase in net income for the first quarter of 2026, driven by robust revenue growth across all segments and effective expense management.

Citigroup reported a 16% increase in net income and a 9% rise in revenues for the third quarter of 2025, demonstrating strong performance across its core businesses and continued strategic transformation.

Citigroup reported a 25% increase in net income for the second quarter of 2025, driven by robust revenue growth across all five business segments and disciplined expense management.

Citigroup's Q1 2025 results showcase improved business performance with a 21% increase in net income, driven by revenue growth and disciplined expense management.

Citigroup's Q3 2024 earnings reveal a 3% revenue increase excluding divestiture impacts, alongside a 1% expense decrease, but also a significant rise in credit costs.

Citigroup's second quarter of 2024 shows a 4% revenue increase and a 2% expense decrease, demonstrating improved business performance and strategic execution.

Citigroup's 2024 Form 10-K reveals a year of improved business performance, strategic transformation, and shareholder returns amidst macroeconomic uncertainties.

Citigroup's 10-K filing details the classes of securities registered under the Securities Exchange Act of 1934, including common stock, preferred stock, and trust preferred securities.

Citigroup Director Casper von Koskull acquired shares through dividend reinvestment and deferred compensation, increasing his beneficial ownership.

Citigroup Inc. director James S. Turley reported transactions involving common stock, including dividend equivalent reinvestments and deferred shares.

Citigroup Inc. Director Diana L. Taylor reported transactions involving common stock on July 1, 2026, including dividend reinvestment and deferred share holdings.

Citigroup Inc. Director Gary M. Reiner reported a transaction involving the acquisition of 385 shares of common stock on July 1, 2026, under the company's compensation plan for non-employee directors.

Citigroup Inc. Director Jonathan Paul Moulds acquired shares through dividend reinvestment and deferred share awards.

Citigroup Inc. director Renee Jo acquired shares through dividend reinvestment and deferred stock plans.

Citigroup supplements its proxy statement with details on the compensation package offered to Viswas Raghavan, Head of Banking and Executive Vice Chair, to incentivize him to join the firm.

Citigroup Inc. announces its 2025 Annual Meeting and encourages stockholders to vote on key proposals by April 28, 2025.

Citigroup's 2025 Proxy Statement outlines key proposals for stockholder vote, including director elections, executive compensation, and amendments to the stock incentive plan, alongside detailed corporate governance and sustainability highlights.

A stockholder proposal regarding director election resignation bylaws has been withdrawn from Citigroup's upcoming Annual Meeting.

Citigroup has released its 2023 Annual Report and 2024 Proxy Statement, detailing the past year's results and key events, including a letter from CEO Jane Fraser.

Citigroup Inc. is holding its annual shareholder meeting on April 30, 2024, where shareholders will vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and several shareholder proposals.

Citigroup Inc reported 11,343 holdings worth $302.7B for the period ended June 30, 2026.

Citigroup Inc. has filed its quarterly Form 13F, reporting holdings across 11,050 securities with a total value of over $234 billion.

Citigroup Inc. has filed its Q4 2025 13F-HR report, revealing over $226.58 billion in managed assets across 12,467 holdings.

Citigroup Inc. has filed its Form 13F-HR, revealing a substantial portfolio of $224.31 billion across 14,658 positions for the quarter ended September 30, 2025.

Citigroup Inc. has filed its Form 13F-HR for the quarter ended June 30, 2025, disclosing equity holdings valued at over $203.5 billion across 15,854 positions.

Citigroup's latest 13F filing showcases a diverse portfolio with significant investments across various sectors and geographies, totaling nearly $196 billion.

Citigroup Inc. and its subsidiaries have reported beneficial ownership of 14,636,273 ordinary shares, representing 6.0% of PureTech Health plc.

Vanguard Capital Management has reported beneficial ownership of 126,457,408 shares of Citigroup Inc. common stock, representing 7.22% of the class.

The Vanguard Group has filed an amended Schedule 13G for Citigroup Inc., reporting zero beneficial ownership following an internal realignment.

Citigroup entities have reported a 6.4% beneficial ownership stake in Wolfspeed, Inc., totaling 2,879,188 common shares.

Citigroup Inc. and its affiliates have reported beneficial ownership of 8.3% of Smartrent, Inc.'s Class A Common Stock.

Citigroup and its affiliates have disclosed a 5.5% beneficial ownership stake in Puretech Health Plc, holding over 13.2 million ordinary shares.